ClinicalTrials.gg
CompletedNCT00236184Updated Apr 6, 2010Results posted

E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers

A Phase 3 interventional study of rabeprazole sodium and Placebo in Heartburn, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2010-04-06.

Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
629
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Heartburn with a site in United States — 5 open to participants now, 7 under way, 1 of them phase 3. Heartburn · United States.

Enrollment
9th of 66
629 · median 98
Started
2005
with 3 others
Phase 3
18 of 76
none open now
Registered
5th of 76
by date
Lead sponsor
3 of 76
Eisai Inc.

Among the 76 studies in Heartburn with a site in United States, this one is the 9th largest by enrollment of the 66 interventional ones that give a count, is one of 4 that started in 2005, is one of 18 in phase 3, and was the 5th registered.

Heartburn

154 studies on the registry are indexed under Heartburn; 12 are open to participants now.

Browse Heartburn studies →

Open to participants now

5 of the 76 studies in Heartburn with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Heartburn studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Heartburn with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the safety and efficacy of rabeprazole sodium 10 mg in treating frequent heartburn.

Read the detailed description

This is a multicenter, double-blind, randomized, placebo-controlled study to investigate the safety and efficacy of rabeprazole 10 mg in treating frequent heartburn. The study will last for up to five weeks and consists of the following three phases: a one to two week screening period that includes a one-week, single-blind, placebo run-in phase, a two week double-blind, randomized treatment phase, and a one week single-blind, placebo follow-up phase.

03

Conditions studied

  • Heartburn

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients > 18 years of age.
  2. If female, not of by reason of surgery or menopause, or of childbearing potential, but using an approved method of since the last menstrual period. Females of childbearing potential must have a negative serum pregnancy test before starting the study.
  3. Patients must report a history of heartburn at least two days per week over the past month.

Exclusion criteria

Exclusion Criteria:

  1. History of erosive esophagitis verified by endoscopy.
  2. History of gastroesophageal reflux disease (GERD) diagnosed by a physician.
  3. Patients who have a history of Barrett's esophagus or esophageal stricture.
  4. Evidence of any medical condition that may interfere with the conduct of the study, the interpretation of study results, or the health of the patient during the study.
  5. Patients who require continuous use of proton pump inhibitors, histamine receptor (H2) blockers, or prokinetics. Prior intermittent use of these agents is permitted if they are discontinued at least three days prior to the run-in phase. The H2 blocker, cimetidine (Tagamet®), must be discontinued for at least seven days before the study drug is administered.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
629 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Oral placebo tablet

    Other: Placebo

  • Experimental
    Rabeprazole sodium 10 mg

    oral rabeprazole 10 mg enteric-coated tablet

    Drug: rabeprazole sodium

Interventions

  • Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.

    Also known as: Aciphex

  • OtherPlacebo

    Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.

06

What researchers measure

Primary outcomes

  1. Complete Heartburn Relief During the First Full 24-Hour Period in the ITT Population.

    Subject was considered "complete relief" if he/she did not heartburn during the nighttime of the first dose date and no heartburn during the daytime of 1 day after the first dose date. The difference in complete relief within the first 24 hours between treatment groups was tested using a continuity corrected chi-square test without adjustment baseline heartburn severity.

    Time frame: first 24 hours

Secondary outcomes

  1. Summary of Percentage of Heartburn-free Daytimes, Intent-to-Treat (ITT) Population

    comparison between placebo and treatment will be analyzed using two-sample t-test.

    Time frame: 14-day treatment period.

  2. Summary of Percentage of Heartburn-Free Nighttimes,Intent-to-Treat (ITT) Population

    comparison between placebo and treatment will be analyzed using two-sample t-test.

    Time frame: 14-day treatment period.

  3. Change From Baseline in Average Regurgitation Severity Score Between Placebo and Rabeprazole.

    comparison between placebo and treatment will be analyzed using two-sample t-test.

    Time frame: 14-day treatment period.

  4. Change From Baseline in Average Belching Severity Score Between Placebo and Rabeprazole.

    comparison between placebo and treatment will be analyzed using two-sample t-test.

    Time frame: 14-day treatment period.

07

Results

Posted Oct 1, 2009

Participant flow

This study was recruited at 39 centers in the US during the period of 10-Oct-2005 and 16-Mar-2006.

Participant flow — Overall Study
MilestonePlaceboRabeprazole 10 mg
Started310319
Completed292308
Not completed1811
Withdrew: Adverse event52
Withdrew: Lack of efficacy01
Withdrew: Lost to follow-up34
Withdrew: Physician decision11
Withdrew: Withdrawal by subject30
Withdrew: Protocol violation30
Withdrew: Non-compliance with study drug21
Withdrew: Other12

Outcome measures

SecondarySummary of Percentage of Heartburn-free Daytimes, Intent-to-Treat (ITT) Population

comparison between placebo and treatment will be analyzed using two-sample t-test.

Time frame:
14-day treatment period.
Reported as:
Mean · Percentage of participants

Results for this outcome have not been posted.

SecondarySummary of Percentage of Heartburn-Free Nighttimes,Intent-to-Treat (ITT) Population

comparison between placebo and treatment will be analyzed using two-sample t-test.

Time frame:
14-day treatment period.
Reported as:
Mean · Percentage of participants

Results for this outcome have not been posted.

SecondaryChange From Baseline in Average Regurgitation Severity Score Between Placebo and Rabeprazole.

comparison between placebo and treatment will be analyzed using two-sample t-test.

Time frame:
14-day treatment period.
Reported as:
Mean

Results for this outcome have not been posted.

SecondaryChange From Baseline in Average Belching Severity Score Between Placebo and Rabeprazole.

comparison between placebo and treatment will be analyzed using two-sample t-test.

Time frame:
14-day treatment period.
Reported as:
Mean

Results for this outcome have not been posted.

PrimaryComplete Heartburn Relief During the First Full 24-Hour Period in the ITT Population.

Subject was considered "complete relief" if he/she did not heartburn during the nighttime of the first dose date and no heartburn during the daytime of 1 day after the first dose date. The difference in complete relief within the first 24 hours between treatment groups was tested using a continuity corrected chi-square test without adjustment baseline heartburn severity.

Time frame:
first 24 hours
Reported as:
Number · participants
Complete Heartburn Relief During the First Full 24-Hour Period in the ITT Population.
participantsPlaceboRabeprazole 10 mg
Complete Heartburn Relief During the First Full 24-Hour Period in the ITT Population.114163
Statistical analysis
  • Placebo vs Rabeprazole 10 mg · Chi-squared, Corrected · p = <0.001

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/310 (0.6%)4/310 (1.3%)
Rabeprazole 10 mg—1/319 (0.3%)7/319 (2.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboRabeprazole 10 mg
Appendicitis perforatedGastrointestinal disorders1/3100/319
abortion spontaneousPregnancy, puerperium and perinatal conditions1/3100/319
Chest painCardiac disorders0/3101/319
Most frequent other events
Most frequent other events
EventPlaceboRabeprazole 10 mg
NasopharyngitisInfections and infestations4/3107/319

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboRabeprazole 10 mgTotal
<=18 years000
Between 18 and 65 years285298583
>=65 years252146
Age Continuous
Age Continuous(years)PlaceboRabeprazole 10 mgTotal
Mean45.4 ± 13.344.1 ± 14.444.7 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRabeprazole 10 mgTotal
Female198186384
Male112133245
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboRabeprazole 10 mgTotal
American Indian or Alaska Native224
Asian459
Native Hawaiian or Other Pacific Islander000
Black or African American253156
White236248484
More than one race000
Unknown or Not Reported433376
Region of Enrollment
Region of Enrollment(participants)PlaceboRabeprazole 10 mgTotal
United States310319629
08

Study locations

1 site
  • Jeffrey L. Newman
    Vista, California 92084, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Mar 2006 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2009, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2005
First posted
Oct 12, 2005
Start
Oct 2005
Primary completionActual
Mar 2006
CompletionActual
Jun 2008
Results first posted
Oct 1, 2009
Last update
Apr 6, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00236184
Lead sponsor
Eisai Inc.
First posted
Oct 12, 2005
Start date
Oct 2005
Primary completion
Mar 2006
Completion
Jun 2008
Results posted
Oct 1, 2009
Last update
Apr 6, 2010

Study contacts

Yufang Lu, MD, PhD
study director · Eisai Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion